RxDoctor Payments DataLook up a doctor →

Joe Pouzar, MD

Family Medicine · Houston, TXNPI 1801803127

Payments from drug & device makers

$10,654,119in general payments, 2019–2025

Across 2,070 payments — averaging $5146.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$3.4M
  • AbbVie$3.2M
  • Pfizer$906K
  • Intercept Pharmaceuticals, Inc.$510K
  • Romark Laboratories, LC$365K
  • Regeneron$328K
  • plus $2M from 54 others
$88,233in research payments, 2019–2025

Across 49 payments — averaging $1800.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$58K
  • Eli Lilly$26K
  • Seikagaku Corporation$3K
  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC112$3,354,771
AbbVie(2 entities)769$3,185,628
Pfizer81$906,304
Intercept Pharmaceuticals, Inc.146$509,894
Romark Laboratories, LC2$364,849
Regeneron43$328,183
AstraZeneca81$327,869
H. Lundbeck A S19$314,229
Eisai Inc.144$243,529
Eli Lilly5$198,267
Vivus LLC25$191,990
GSK55$89,162
Boehringer Ingelheim21$77,352
La Jolla Pharmaceutical Company30$76,963
Astrazeneca UK Limited2$76,796
Novartis8$50,117
Merck33$45,931
Radius Health, Inc.26$45,836
Gilead6$40,994
Sanofi US Services Inc.31$37,387
Otsuka Pharmaceutical Development & Commercialization, Inc.2$26,202
Sage Therapeutics, LLC17$25,820
Akcea Therapeutics, Inc.4$24,343
Novo Nordisk AS36$23,174
Bayer32$12,893
Pacira Therapeutics, Inc.1$12,534
Bristol Myers Squibb6$11,409
Kowa Research Institute, Inc.6$8,627
Acadia Pharmaceuticals Inc1$8,500
Braintree Laboratories, Inc.5$7,066
GRT US Holding, Inc.7$6,658
Ionis Pharmaceuticals, Inc.2$5,079
Lexicon Pharmaceuticals, Inc.5$4,758
Astrazeneca AB1$2,500
Lilly USA, LLC24$1,895
Novo Nordisk66$1,424
Organon9$689
Amgen(2 entities)48$675
Amarin Pharma, Inc.38$653
Boehringer Ingelheim RCV GmbH & Co KG1$487
Astellas Pharma US Inc22$433
E.r. Squibb & Sons, L.L.C.1$286
Esperion Therapeutics, Inc.9$221
Genentech USA, Inc.3$190
Alnylam Pharmaceuticals Inc.4$182
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$172
Exact Sciences9$162
Abbott5$108
Takeda Pharmaceuticals U.S.A., Inc.6$98
Sanofi-aventis U.S. LLC6$87
Johnson & Johnson5$77
Verity Pharmaceuticals Inc.4$73
Teva Pharmaceuticals USA, Inc.5$59
Axsome Therapeutics, Inc.2$58
Arbor Pharmaceuticals, Inc.4$50
Ardelyx, Inc.2$50
Sumitomo Pharma America, Inc.2$38
Currax Pharmaceuticals LLC3$37
Shire North American Group Inc2$34
Vertex1$32

How this compares

$10,654,119 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$81,857
Medicare patients
225
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →